A novel therapy for ataxia telangiectasia that delivers dexamethasone sodium phosphate through red blood cells is both promising and impressive in a new phase 3 trial, experts say.
EryDel SpA EryDel to Present its Phase 3 Study Results for Ataxia Telangiectasia at the American Academy of Neurology 2022 Annual Meeting 05-Apr-2022 / 08:00 CET/CEST EryDel to Present its Phase 3 Study Results for Ataxia Telangiectasia at the American Academy of Neurology 2022 Annual Meeting BR.
BRESSO (MILANO), ITALY / ACCESSWIRE / April 5, 2022 / EryDel SpA, a global late-stage biotech company aimed at developing and commercializing therapies for the treatment of rare diseases delivered by its